MOLECULAR PARTNERS ADS/1 (6ML0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MOLECULAR PARTNERS ADS/1 (6ML0) has a cash flow conversion efficiency ratio of -0.184x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.79 Million ≈ $-12.62 Million USD) by net assets (€58.54 Million ≈ $68.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 6ML0 company net worth for the company's overall valuation and market capitalisation.
MOLECULAR PARTNERS ADS/1 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how MOLECULAR PARTNERS ADS/1's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MOLECULAR PARTNERS ADS/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MOLECULAR PARTNERS ADS/1 ranked by their cash flow conversion efficiency. Explore cash flow quality index of MOLECULAR PARTNERS ADS/1 to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harmony Electronics
TWO:8182
|
-0.019x |
|
Innate Pharma
NASDAQ:IPHA
|
1.078x |
|
Red Robin Gourmet Burgers Inc
NASDAQ:RRGB
|
-0.071x |
|
LEWAG Holding Aktiengesellschaft
F:KGR
|
-0.084x |
|
Komelon Corporation
KQ:049430
|
0.017x |
|
American Well Corp
NYSE:AMWL
|
-0.004x |
|
Turk Prysmian Kablo ve Sistemleri AS
IS:PRKAB
|
0.312x |
|
Gateway Mining Ltd
AU:GML
|
-0.013x |
Annual Cash Flow Conversion Efficiency for MOLECULAR PARTNERS ADS/1 (2021–2025)
The table below shows the annual cash flow conversion efficiency of MOLECULAR PARTNERS ADS/1 from 2021 to 2025. View MOLECULAR PARTNERS ADS/1 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €80.33 Million ≈ $93.92 Million |
€-51.26 Million ≈ $-59.92 Million |
-0.638x | -52.53% |
| 2024-12-31 | €141.64 Million ≈ $165.59 Million |
€-59.25 Million ≈ $-69.27 Million |
-0.418x | -25.08% |
| 2023-12-31 | €176.43 Million ≈ $206.26 Million |
€-59.01 Million ≈ $-68.98 Million |
-0.334x | -166.33% |
| 2022-12-31 | €235.17 Million ≈ $274.93 Million |
€118.57 Million ≈ $138.62 Million |
0.504x | +159.47% |
| 2021-12-31 | €107.29 Million ≈ $125.43 Million |
€-90.95 Million ≈ $-106.33 Million |
-0.848x | -- |
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more